Compare FirstEnergy Corp. (FE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Merck & Co., Inc. — how do they compare? FirstEnergy Corp. trades at $44.9 (market cap $25.95B), while Merck & Co., Inc. trades at $141.98 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 13.5× FirstEnergy Corp.'s market cap, and FirstEnergy Corp. pays the higher dividend (4.15%). Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and Merck & Co., Inc. for 98 Days on average.
| FE | MRK | |
|---|---|---|
Market Cap | $25.95B | $351.28B |
Volume | 5,643,833 | 7,969,665 |
Sector | Utilities | Health |
52-Week High | $51.91 | $156.43 |
52-Week Low | $43.04 | $82.49 |
Typical Hold Time | 71 Days | 98 Days |
Enterprise Value | $54.87B | $398.04B |
Dividend Yield | 4.15% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.58, up 0.72% today, with a bullish technical signal but mixed earnings history. Revenue grew to $15.09B in 2025, with a net income margin of 6.86%, while valuation ratios like P/E of 23.84 and P/S of 1.63 suggest moderate pricing. Recent news highlights dividend declarations and a $36B Energize365 investment plan, supporting long-term growth amid rising data-center demand.
Outlook is positive with a consensus price target of $52.80, implying 18% upside, but risks include high debt levels and volatile cash flows. Analyst sentiment is mixed with 43% buy ratings, while institutional ownership trends show recent stake increases, indicating cautious optimism for steady utility returns.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
